2018
Cannabis
Opioids
December 4, 2018
CMA response: Health Canada consultation on Canadian drugs and substances strategy
The CMA supports a public health approach to substance use issues, and a comprehensive national strategy to address the harms associated with psychoactive drugs
Opioids
August 30, 2018
Open letter to Premier Doug Ford and Health Minister Christine Elliott
CMA signs an open letter reinforcing the need to provide greater and more equitable access to supervised consumption sites i…
Opioids
August 14, 2018
CMA response: Consultation on Regulatory Amendments regarding Tramadol
To protect Canadians’ health and safety, the CMA advises tramadol be placed on Schedule 1 of the Controlled Drugs and Substances Act
Opioids
July 18, 2018
CMA response: Consultation on Restriction of Marketing and Advertising of Opioids
The CMA supports Health Canada’s efforts to restrict the ability of drug manufacturers to advertise opioids to health care practitioners2017
Opioids
November 7, 2017
CMA submission on Non-Prescription Availability of Low-Dose Codeine Products
In the interest of promoting public health and patient safety, the CMA endorses the requirement that all products containing low-dose codeine be sold by prescription only
Opioids
August 22, 2017
Opioids Session on Periscope
At CMA’s 150th General Council in Quebec City, experts discuss the opioid crisis in Canada as part of a Facing Ca…
Opioids
April 6, 2017
CMA submission on the study of Bill C-37: An Act to amend the Controlled Drugs and Substances Act
The CMA makes recommendations to the Senate Committee on Legal and Constitutional Affairs about Bill C-37, An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts2016
Opioids
October 18, 2016
CMA statement to the House of Commons Standing Committee on Health
Dr. Jeff Blackmer, CMA Vice-president of Medical Professionalism, speaks before the House of Commons Standing Committee on Health about Canada’s escalating public health crisis related to problematic opioid and fentanyl use
Opioids
March 19, 2016
CMA response: Consultation on the Prescription Drug List: Naloxone
In response to Health Canada’s consultation on the prescription drug list, the CMA advocates for increased access to naloxone for emergency treatment of opioid overdose outside hospitals2015
Opioids
May 30, 2015
Harms Associated with Opioids and other Psychoactive Prescription Drugs
A CMA policy offers background on the harms associated with opioids and other psychoactive prescription drugs subject and ou…
Opioids
May 14, 2015
CMA submission to the Senate Standing Committee on Legal and Constitutional Affairs on Bill C-2: An Act to Amend the Controlled Drugs and Substances Act
The CMA presents its concerns with Bill C-2 before the Senate Standing Committee on Legal and Constitutional Affairs, including that the new legislation could make it harder to create new supervised consumption sites2014
Opioids
October 28, 2014
CMA submission to the House of Commons Standing Committee on Public Safety and National Security on Bill C-2: An Act to Amend the Controlled Drugs and Substances Act
Concerns about the potential of Bill C-2 impede the creation of new supervised consumption sites feature in the CMA’s submission to the House of Commons Standing Committee on Public Safety and National Security
Opioids
August 26, 2014
CMA response on Tamper Resistance under the Controlled Drugs and Substances Act
The CMA advocates for regulations requiring products containing certain controlled substances to be tamper-resistant as a condition for sale in Canada
Opioids
March 26, 2014
CMA submission on the Senate study on prescription pharmaceuticals
In support of the Senate Committee on Social Affairs, Science and Technology study on prescription pharmaceuticals in Canada, the CMA recommends ways for the federal government to address the unintended consequences of prescription pharmaceuticals and support public health, quality care and patient safety
Opioids
March 17, 2014
CMA submission on the Review of Controlled Drugs and Substances Act
The CMA’s response to Health Canada’s consultation on the Controlled Drugs and Substances Act and its regulations recommends new measures and mechanisms for improving public health and safety, including enhancements to controlled substance approval, labelling and safety monitoring2013
Opioids
November 27, 2013